Pages that link to "Q67254517"

The following pages link to Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin (Q67254517):

Displaying 25 items.

• Nonsurgical treatment of hepatocellular carcinoma (Q32059984) (← links)
• Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma (Q33379651) (← links)
• Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy. (Q33838824) (← links)
• Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uraci (Q34225481) (← links)
• Liver cancer (Q34269663) (← links)
• Randomized clinical trials in hepatocellular carcinoma and biliary cancer (Q34586251) (← links)
• Expression of P‐glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: Clinical correlation (Q34742986) (← links)
• Current management of advanced hepatocellular carcinoma (Q37072518) (← links)
• Systemic therapy in hepatocellular carcinoma (Q37135733) (← links)
• Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. (Q39289689) (← links)
• Etoposide: A Semisynthetic Epipodophyllotoxin Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects and Use as an Antineoplastic Agent (Q40141842) (← links)
• Transduction of hepatocellular carcinoma (HCC) using recombinant adeno-associated virus (rAAV): in vitro and in vivo effects of genotoxic agents (Q40868185) (← links)
• Management of pediatric liver tumors. (Q41340282) (← links)
• Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future (Q42343451) (← links)
• Hepatocellular carcinoma (Q57696098) (← links)
• Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717 (Q58212638) (← links)
• Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies (Q67507656) (← links)
• Primary liver cancer in Hong Kong (Q67598879) (← links)
• Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma (Q69333900) (← links)
• Randomized controlled study of mitomycin C/carboquone/5-fluorouracil/OK-432 (MQ-F-OK) therapy and mitomycin C/5-fluorouracil/doxorubicin (FAM) therapy against advanced liver cancer (Q69489268) (← links)
• Hepatic neoplasia (Q70082053) (← links)
• A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma (Q71769472) (← links)
• Combination therapy consisting of arterial infusion chemotherapy (EPF, EAP) and transcatheter arterial embolization (TAE) (Q72314404) (← links)
• Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study (Q74202029) (← links)
• Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma (Q80224586) (← links)